Overview
Can You Diagnose This Patient with Impaired Balance and Paresthesia?
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
When your patient presents with symptoms such as impaired balance and paresthesia, what might you first suspect and can you reach the right diagnosis? Put your diagnostic skills to the test! In just 15 minutes, navigate through real-world cases and upon completion, hear faculty insights on the implications of your decisions along with rationales for appropriate next steps to aid in making a final diagnosis, as well as evidence-based treatment strategies. Apply the latest scientific evidence into evolving treatment plans and improve the management of your patients today!
This educational activity is intended for neurologists, neuromuscular specialists, immunologists, primary care providers, hospitalists, emergency physicians, advanced practitioners, and nurses who manage undiagnosed patients presenting with impaired balance and paresthesia.
Impaired balance and paresthesia may be indicative of a number of heterogenous conditions, often leading to an incorrect or delayed diagnosis. Further, these symptoms may lead to severe disability if left untreated. An accurate, prompt diagnosis is paramount to ensuring that patients receive treatment to reduce disability. This educational course will provide clinicians with strategies to facilitate timely diagnoses and individualize therapeutic approaches.
The learning objectives for this case challenge have been blinded so as to not give away the correct case diagnoses.
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Jeffrey Allen, MD
Professor, Department of Neurology
University of Minnesota
Minneapolis, MN
Professor, Department of Neurology
University of Minnesota
Minneapolis, MN
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Jeffrey Allen, MD
Advisory Board: Argenx, CSL Behring, Octapharma, Takeda
Consulting Agreements: Argenx, Grifols, ImmunoPharma, Immunovant, Sanofi, Takeda
Speakers Bureau: Alexion, Alnylam, Argenx, Astra Zeneca, Takeda
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: immunosuppressants, B cell-depleting agents, anti–tumor necrosis factor-α therapies
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
